Profibrotic Signaling and HCC Risk during Chronic Viral Hepatitis: Biomarker Development
Despite breakthroughs in antiviral therapies, chronic viral hepatitis B and C are still the major causes of liver fibrosis and hepatocellular carcinoma (HCC). Importantly, even in patients with controlled infection or viral cure, the cancer risk cannot be fully eliminated, highlighting a persisting...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-03-01
|
| Series: | Journal of Clinical Medicine |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2077-0383/10/5/977 |
| _version_ | 1797416357853134848 |
|---|---|
| author | Alessia Virzì Victor Gonzalez-Motos Simona Tripon Thomas F. Baumert Joachim Lupberger |
| author_facet | Alessia Virzì Victor Gonzalez-Motos Simona Tripon Thomas F. Baumert Joachim Lupberger |
| author_sort | Alessia Virzì |
| collection | DOAJ |
| description | Despite breakthroughs in antiviral therapies, chronic viral hepatitis B and C are still the major causes of liver fibrosis and hepatocellular carcinoma (HCC). Importantly, even in patients with controlled infection or viral cure, the cancer risk cannot be fully eliminated, highlighting a persisting oncogenic pressure imposed by epigenetic imprinting and advanced liver disease. Reliable and minimally invasive biomarkers for early fibrosis and for residual HCC risk in HCV-cured patients are urgently needed. Chronic infection with HBV and/or HCV dysregulates oncogenic and profibrogenic signaling within the host, also displayed in the secretion of soluble factors to the blood. The study of virus-dysregulated signaling pathways may, therefore, contribute to the identification of reliable minimally invasive biomarkers for the detection of patients at early-stage liver disease potentially complementing existing noninvasive methods in clinics. With a focus on virus-induced signaling events, this review provides an overview of candidate blood biomarkers for liver disease and HCC risk associated with chronic viral hepatitis and epigenetic viral footprints. |
| first_indexed | 2024-03-09T06:02:03Z |
| format | Article |
| id | doaj.art-2c1b725f3f34434788c954531287a8b5 |
| institution | Directory Open Access Journal |
| issn | 2077-0383 |
| language | English |
| last_indexed | 2024-03-09T06:02:03Z |
| publishDate | 2021-03-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Journal of Clinical Medicine |
| spelling | doaj.art-2c1b725f3f34434788c954531287a8b52023-12-03T12:07:48ZengMDPI AGJournal of Clinical Medicine2077-03832021-03-0110597710.3390/jcm10050977Profibrotic Signaling and HCC Risk during Chronic Viral Hepatitis: Biomarker DevelopmentAlessia Virzì0Victor Gonzalez-Motos1Simona Tripon2Thomas F. Baumert3Joachim Lupberger4Université de Strasbourg, 67000 Strasbourg, FranceUniversité de Strasbourg, 67000 Strasbourg, FranceUniversité de Strasbourg, 67000 Strasbourg, FranceUniversité de Strasbourg, 67000 Strasbourg, FranceUniversité de Strasbourg, 67000 Strasbourg, FranceDespite breakthroughs in antiviral therapies, chronic viral hepatitis B and C are still the major causes of liver fibrosis and hepatocellular carcinoma (HCC). Importantly, even in patients with controlled infection or viral cure, the cancer risk cannot be fully eliminated, highlighting a persisting oncogenic pressure imposed by epigenetic imprinting and advanced liver disease. Reliable and minimally invasive biomarkers for early fibrosis and for residual HCC risk in HCV-cured patients are urgently needed. Chronic infection with HBV and/or HCV dysregulates oncogenic and profibrogenic signaling within the host, also displayed in the secretion of soluble factors to the blood. The study of virus-dysregulated signaling pathways may, therefore, contribute to the identification of reliable minimally invasive biomarkers for the detection of patients at early-stage liver disease potentially complementing existing noninvasive methods in clinics. With a focus on virus-induced signaling events, this review provides an overview of candidate blood biomarkers for liver disease and HCC risk associated with chronic viral hepatitis and epigenetic viral footprints.https://www.mdpi.com/2077-0383/10/5/977HBVHCVbiomarkersliver diseaseHCCcure |
| spellingShingle | Alessia Virzì Victor Gonzalez-Motos Simona Tripon Thomas F. Baumert Joachim Lupberger Profibrotic Signaling and HCC Risk during Chronic Viral Hepatitis: Biomarker Development Journal of Clinical Medicine HBV HCV biomarkers liver disease HCC cure |
| title | Profibrotic Signaling and HCC Risk during Chronic Viral Hepatitis: Biomarker Development |
| title_full | Profibrotic Signaling and HCC Risk during Chronic Viral Hepatitis: Biomarker Development |
| title_fullStr | Profibrotic Signaling and HCC Risk during Chronic Viral Hepatitis: Biomarker Development |
| title_full_unstemmed | Profibrotic Signaling and HCC Risk during Chronic Viral Hepatitis: Biomarker Development |
| title_short | Profibrotic Signaling and HCC Risk during Chronic Viral Hepatitis: Biomarker Development |
| title_sort | profibrotic signaling and hcc risk during chronic viral hepatitis biomarker development |
| topic | HBV HCV biomarkers liver disease HCC cure |
| url | https://www.mdpi.com/2077-0383/10/5/977 |
| work_keys_str_mv | AT alessiavirzi profibroticsignalingandhccriskduringchronicviralhepatitisbiomarkerdevelopment AT victorgonzalezmotos profibroticsignalingandhccriskduringchronicviralhepatitisbiomarkerdevelopment AT simonatripon profibroticsignalingandhccriskduringchronicviralhepatitisbiomarkerdevelopment AT thomasfbaumert profibroticsignalingandhccriskduringchronicviralhepatitisbiomarkerdevelopment AT joachimlupberger profibroticsignalingandhccriskduringchronicviralhepatitisbiomarkerdevelopment |